TrialThe Journal of infectious diseases2019

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya.

Gaudensia Mutua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.